• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Should Agilent’s (A) Digital Pathology Push and Buybacks Prompt a Portfolio Rethink for Investors?

    Simply Wall St·09/07/2026 14:25:29
    語音播報
    • In late August and early September 2026, Agilent Technologies expanded its diagnostics portfolio with the past U.S. FDA-cleared launch of the S540MD digital slide scanner and introduced the compact Cary 635 FTIR spectrometer, while also completing US$346.74 million of share repurchases under its existing buyback program.
    • These launches, paired with raised 2026 revenue guidance and solid third-quarter earnings growth, highlight how Agilent is using digital pathology and modular lab tools to support laboratory efficiency and higher-value recurring solutions.
    • We’ll now examine how the FDA-cleared S540MD scanner, in particular, may influence Agilent’s investment narrative around digital diagnostics growth.

    We've uncovered the 11 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

    Agilent Technologies Investment Narrative Recap

    To own Agilent, you need to believe it can keep shifting its lab hardware base toward higher-value, recurring diagnostics and software, while defending margins against tariffs and supply chain complexity. The new S540MD digital slide scanner and Cary 635 FTIR launches, together with raised 2026 revenue guidance, support the near term catalyst of expanding recurring, workflow-centric solutions. The biggest risk, in my view, remains execution pressure and rising costs as global operations and competition become more complex, and the recent news does not materially change that.

    Among the recent announcements, the FDA-cleared U.S. launch of the S540MD scanner looks most relevant, because it anchors Agilent more firmly in digital pathology workflows that can pull through consumables, software and services. If adoption in high volume labs scales as intended, this type of instrument platform can reinforce the existing catalyst around higher-margin recurring revenue, while still sitting alongside the traditional capital equipment cycles that many investors already focus on.

    Yet while digital diagnostics can help, investors should still be aware that tariff driven cost pressures and rising supply chain complexity could...

    Read the full narrative on Agilent Technologies (it's free!)

    Agilent Technologies' narrative projects $9.0 billion revenue and $2.2 billion earnings by 2029. This requires 7.0% yearly revenue growth and a roughly $0.8 billion earnings increase from $1.4 billion today.

    Uncover how Agilent Technologies' forecasts yield a $174.90 fair value, a 16% upside to its current price.

    Exploring Other Perspectives

    A 1-Year Stock Price Chart
    A 1-Year Stock Price Chart

    Four Simply Wall St Community fair value estimates for Agilent range from US$150.54 to US$191.33, showing how far apart individual views can be. As you weigh those opinions against Agilent’s push into digital pathology and recurring solutions, consider how quickly laboratories might actually adopt new platforms like the S540MD and what that could mean for the company’s ability to offset rising operating and competitive pressures over time.

    Explore 4 other fair value estimates on Agilent Technologies - why the stock might be worth just $150.54!

    The Verdict Is Yours

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    • A great starting point for your Agilent Technologies research is our analysis highlighting 3 key rewards that could impact your investment decision.
    • Our free Agilent Technologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Agilent Technologies' overall financial health at a glance.

    Searching For A Fresh Perspective?

    Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.